Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

December 1, 2026

Conditions
Traumatic Brain InjuryAgitation,Psychomotor
Interventions
DRUG

Dexmedetomidine

DEX 4 mcg/100 ml at a starting dose of 0.6 mcg/kg/hour and increased by 0.2 mcg/kg/hour every 30 minutes up to final dose of 1.4 mcg/kg/hour.

DRUG

Placebo

NaCl 0.9% 100ml

All Listed Sponsors
collaborator

Canadian Critical Care Trials Group

OTHER

lead

Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

OTHER